Overview

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluoxetine
Olanzapine